AR029613A1 - Un vehiculo biocompatible estable, no acuoso, de fase unica, formulaciones no acuosas que comprenden el vehiculo y por lo menos un agente benefico suspendido en el mismo y metodos para preparar el vehiculo y las formulaciones. . - Google Patents
Un vehiculo biocompatible estable, no acuoso, de fase unica, formulaciones no acuosas que comprenden el vehiculo y por lo menos un agente benefico suspendido en el mismo y metodos para preparar el vehiculo y las formulaciones. .Info
- Publication number
- AR029613A1 AR029613A1 ARP000100524A ARP000100524A AR029613A1 AR 029613 A1 AR029613 A1 AR 029613A1 AR P000100524 A ARP000100524 A AR P000100524A AR P000100524 A ARP000100524 A AR P000100524A AR 029613 A1 AR029613 A1 AR 029613A1
- Authority
- AR
- Argentina
- Prior art keywords
- vehicle
- formulations
- beneficial agent
- methods
- stable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un vehículo viscoso biocompatible estable, no acuoso, de fase unica, apto para la suspension de agentes benéficos y para dispensar dicho agente benéfico de manera homogénea durante un período de tiempo prolongado a la temperatura corporal y con bajos índices de flujo. El vehículo viscoso comprende por lo menos dos componentes seleccionados del grupo que consiste en un solvente, un tensioactivo y un polímero. Formulaciones que comprenden por lo menos un agente benéfico, como por ejemplo, un péptido, una proteína, un nucleotido, una hormona, un virus o un anticuerpo, etc., uniformemente suspendido en el vehículo, y que son aptas para ser almacenadas a temperaturas que oscilan entre frío y temperatura corporal durante períodos de tiempo prolongados, y para ser administradas de manera uniforme desde disposiciones para la administracion de fármacos con una velocidad de esfuerzo de corte a la salida entre 1 y 1 x 10-7 s-1; y métodos para preparar el vehículo y las formulaciones.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11917099P | 1999-02-08 | 1999-02-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR029613A1 true AR029613A1 (es) | 2003-07-10 |
Family
ID=22382917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000100524A AR029613A1 (es) | 1999-02-08 | 2000-02-07 | Un vehiculo biocompatible estable, no acuoso, de fase unica, formulaciones no acuosas que comprenden el vehiculo y por lo menos un agente benefico suspendido en el mismo y metodos para preparar el vehiculo y las formulaciones. . |
Country Status (22)
Country | Link |
---|---|
EP (2) | EP1152749B1 (es) |
JP (1) | JP4861551B2 (es) |
KR (2) | KR100858856B1 (es) |
CN (1) | CN1232244C (es) |
AR (1) | AR029613A1 (es) |
AT (2) | ATE322889T1 (es) |
AU (1) | AU775904B2 (es) |
CA (1) | CA2361424C (es) |
CO (1) | CO5140096A1 (es) |
CY (1) | CY1119950T1 (es) |
DE (1) | DE60027272T2 (es) |
DK (1) | DK1666026T4 (es) |
ES (2) | ES2379471T5 (es) |
HK (2) | HK1041451B (es) |
HU (1) | HUP0200202A3 (es) |
IL (1) | IL144755A0 (es) |
NO (1) | NO20013861L (es) |
NZ (1) | NZ513441A (es) |
PT (2) | PT1666026E (es) |
TW (2) | TWI292716B (es) |
WO (1) | WO2000045790A2 (es) |
ZA (1) | ZA200106443B (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4931282B2 (ja) * | 2000-10-02 | 2012-05-16 | 日本ケミカルリサーチ株式会社 | 生理活性ペプチド含有粉末 |
US7731947B2 (en) * | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
BR0317421A (pt) * | 2002-12-19 | 2005-11-08 | Alza Corp | Géis de fase única não-aquosa estável e formulações destes para liberação a partir de um dispositivo implantável |
WO2004089335A2 (en) * | 2003-03-31 | 2004-10-21 | Alza Corporation | Non-aqueous single phase vehicles and formulations utilizing such vehicles |
CN100548411C (zh) | 2003-03-31 | 2009-10-14 | 精达制药公司 | 设置有内部压力释放部件的渗透泵 |
US20050118206A1 (en) * | 2003-11-14 | 2005-06-02 | Luk Andrew S. | Surfactant-based gel as an injectable, sustained drug delivery vehicle |
US7772182B2 (en) * | 2004-08-05 | 2010-08-10 | Alza Corporation | Stable suspension formulations of erythropoietin receptor agonists |
US20060141040A1 (en) * | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
JP2008528698A (ja) * | 2005-02-03 | 2008-07-31 | インターシア セラピューティクス,インコーポレイティド | 埋め込み可能なインターフェロン含有デバイス |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
KR101106510B1 (ko) | 2006-05-30 | 2012-01-20 | 인타르시아 세라퓨틱스 인코포레이티드 | 투피스, 내부채널 삼투압 전달 시스템 유동 조절기 |
DK2049081T3 (da) | 2006-08-09 | 2013-02-25 | Intarcia Therapeutics Inc | Osmotiske leveringssystemer og stempelarrangementer |
ES2402172T3 (es) | 2007-04-23 | 2013-04-29 | Intarcia Therapeutics, Inc | Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos |
HUE043228T2 (hu) | 2007-06-22 | 2019-08-28 | Univ Texas | Stabil szubmikron peptid vagy protein részecskék képzése vékonyfilm fagyasztással |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
CA2743789C (en) | 2008-11-16 | 2017-10-31 | Board Of Regents, The Univesity Of Texas System | Low viscosity highly concentrated suspensions |
CN107638562B (zh) | 2009-09-28 | 2022-12-02 | 精达制药公司 | 基本稳态药物递送的快速建立和/或终止 |
CN102869345B (zh) | 2010-03-17 | 2015-02-11 | 诺瓦利克有限责任公司 | 用于治疗眼内压增高的药物组合物 |
EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
CA2834862C (en) | 2011-05-25 | 2019-12-17 | Novaliq Gmbh | Pharmaceutical composition for administration to nails |
PL3192501T3 (pl) | 2011-05-25 | 2020-11-02 | Novaliq Gmbh | Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach |
SG11201401360XA (en) | 2011-10-25 | 2014-05-29 | Onclave Therapeutics Ltd | Antibody formulations and methods |
KR101989648B1 (ko) | 2012-01-23 | 2019-06-14 | 노바리크 게엠베하 | 부분불소화 알칸에 기초한 안정화된 단백질 조성물 |
ES2965828T3 (es) | 2012-09-12 | 2024-04-17 | Novaliq Gmbh | Composiciones de alcano semifluorado |
CA2883002C (en) | 2012-09-12 | 2019-05-21 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
US10273298B2 (en) | 2013-07-23 | 2019-04-30 | Novaliq Gmbh | Stabilized antibody compositions |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US10925639B2 (en) | 2015-06-03 | 2021-02-23 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
CN110403923B (zh) | 2015-09-30 | 2021-09-21 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
EP3722274B1 (en) | 2015-09-30 | 2023-06-07 | Novaliq GmbH | 2-perfluorobutyl pentane for ophthalmic administration |
BR112018073511A2 (pt) | 2016-05-16 | 2019-03-26 | Intarcia Therapeutics, Inc. | polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
DK3442480T3 (da) | 2016-06-23 | 2020-01-13 | Novaliq Gmbh | Fremgangsmåde til topisk indgivelse |
ES2969758T3 (es) | 2016-09-22 | 2024-05-22 | Novaliq Gmbh | Composiciones farmacéuticas para usar en la terapia de la blefaritis |
CN109906085B (zh) | 2016-09-23 | 2024-03-08 | 诺瓦利克有限责任公司 | 含有环孢素的眼用组合物 |
MX2019008006A (es) | 2017-01-03 | 2019-08-29 | Intarcia Therapeutics Inc | Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco. |
AU2018253944B2 (en) | 2017-04-21 | 2022-09-15 | Dermaliq Therapeutics, Inc. | Iodine compositions |
EP3621601A1 (en) | 2017-05-12 | 2020-03-18 | Novaliq GmbH | Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions |
US11723861B2 (en) | 2017-09-27 | 2023-08-15 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
US11896559B2 (en) | 2017-10-04 | 2024-02-13 | Novaliq Gmbh | Opthalmic compositions comprising F6H8 |
SG11202007858VA (en) | 2018-03-02 | 2020-09-29 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
WO2020064556A1 (en) | 2018-09-27 | 2020-04-02 | Novaliq Gmbh | Topical sunscreen formulation |
SG11202102820VA (en) | 2018-10-12 | 2021-04-29 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
CA3167217A1 (en) | 2020-01-13 | 2021-07-22 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2528516A1 (de) † | 1974-07-05 | 1976-01-22 | Sandoz Ag | Neue galenische zubereitung |
JPS5788115A (en) * | 1980-10-06 | 1982-06-01 | Miles Lab | Stable non-aqueous solution of tetracycline antibiotic salt |
DE3320583A1 (de) † | 1983-06-08 | 1984-12-13 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung |
US5385738A (en) * | 1983-10-14 | 1995-01-31 | Sumitomo Pharmaceuticals Company, Ltd. | Sustained-release injection |
JPS61189230A (ja) * | 1985-02-19 | 1986-08-22 | Nippon Kayaku Co Ltd | エトポシド製剤 |
GB8528959D0 (en) * | 1985-11-25 | 1986-01-02 | Leo Pharm Prod Ltd | Chemical compounds |
DE3636123A1 (de) * | 1986-10-23 | 1988-05-05 | Rentschler Arzneimittel | Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten |
JPH0720866B2 (ja) † | 1987-05-15 | 1995-03-08 | 三生製薬株式会社 | エペリゾン又はトルペリゾン或いはそれらの塩類含有経皮適用製剤 |
US5756450A (en) * | 1987-09-15 | 1998-05-26 | Novartis Corporation | Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms |
JP2794022B2 (ja) † | 1988-11-11 | 1998-09-03 | 三生製薬株式会社 | ブナゾシン或いはその塩類含有経皮適用製剤 |
US5112614A (en) * | 1989-09-14 | 1992-05-12 | Alza Corporation | Implantable delivery dispenser |
JPH03236317A (ja) † | 1989-12-06 | 1991-10-22 | Sansei Seiyaku Kk | ドパミン誘導体含有経皮用製剤 |
US5733572A (en) † | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
EP0520119A1 (de) † | 1991-06-17 | 1992-12-30 | Spirig Ag Pharmazeutische Präparate | Neue orale Diclofenaczubereitung |
AU3136293A (en) † | 1991-11-15 | 1993-06-15 | Isp Investments Inc. | Pharmaceutical tablet with pvp having an enhanced drug dissolution rate |
US5314685A (en) † | 1992-05-11 | 1994-05-24 | Agouron Pharmaceuticals, Inc. | Anhydrous formulations for administering lipophilic agents |
WO1994021262A1 (en) | 1993-03-17 | 1994-09-29 | Alza Corporation | Device for the transdermal administration of alprazolam |
GB9309422D0 (en) * | 1993-05-07 | 1993-06-23 | Res Inst Medicine Chem | Chemical compounds |
WO1995001167A2 (en) † | 1993-06-25 | 1995-01-12 | Alza Corporation | Incorporating poly-n-vinyl amide in a transdermal system |
ATE183926T1 (de) | 1993-09-29 | 1999-09-15 | Alza Corp | Hautpermeabilitaetserhöher bestehend aus monoglycerid/laktat estern |
CA2203566C (en) * | 1994-10-24 | 2001-10-23 | Yuko Hosokawa | Percutaneously administration preparation |
US5736159A (en) † | 1995-04-28 | 1998-04-07 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water insoluble drugs in which a passageway is formed in situ |
ATE226075T1 (de) * | 1995-06-06 | 2002-11-15 | Hoffmann La Roche | Pharmazeutische zusammensetzung enthaltend einen inhibitor von proteinase und einen monoglycerid |
US5904935A (en) * | 1995-06-07 | 1999-05-18 | Alza Corporation | Peptide/protein suspending formulations |
DK0836506T4 (da) † | 1995-06-07 | 2012-01-30 | Ortho Mcneil Pharm Inc | Transdermalt plaster til indgivelse af 17-deacetyl norgestimat alene eller i kombination med et østrogen |
US6572879B1 (en) † | 1995-06-07 | 2003-06-03 | Alza Corporation | Formulations for transdermal delivery of pergolide |
US5906830A (en) † | 1995-09-08 | 1999-05-25 | Cygnus, Inc. | Supersaturated transdermal drug delivery systems, and methods for manufacturing the same |
US5766620A (en) † | 1995-10-23 | 1998-06-16 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
WO1998002169A2 (en) † | 1996-07-15 | 1998-01-22 | Alza Corporation | Novel formulations for the administration of fluoxetine |
ES2191834T3 (es) † | 1996-10-24 | 2003-09-16 | Alza Corp | Agentes que facilitan la permeacion y destinados para composiciones, dispositivos y procedimientos de aporte transdermico de medicamentos. |
DE19646392A1 (de) † | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht |
EP0959873B1 (en) | 1996-12-20 | 2006-03-01 | ALZA Corporation | Gel composition and methods |
US20020039594A1 (en) † | 1997-05-13 | 2002-04-04 | Evan C. Unger | Solid porous matrices and methods of making and using the same |
SI9700186B (sl) † | 1997-07-14 | 2006-10-31 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin |
-
2000
- 2000-02-02 CN CNB008035636A patent/CN1232244C/zh not_active Expired - Fee Related
- 2000-02-02 ES ES06075430.6T patent/ES2379471T5/es not_active Expired - Lifetime
- 2000-02-02 AT AT00913350T patent/ATE322889T1/de not_active IP Right Cessation
- 2000-02-02 AU AU34816/00A patent/AU775904B2/en not_active Ceased
- 2000-02-02 JP JP2000596910A patent/JP4861551B2/ja not_active Expired - Fee Related
- 2000-02-02 DE DE60027272T patent/DE60027272T2/de not_active Expired - Lifetime
- 2000-02-02 IL IL14475500A patent/IL144755A0/xx not_active IP Right Cessation
- 2000-02-02 KR KR1020017010037A patent/KR100858856B1/ko active IP Right Grant
- 2000-02-02 NZ NZ513441A patent/NZ513441A/xx not_active IP Right Cessation
- 2000-02-02 HU HU0200202A patent/HUP0200202A3/hu unknown
- 2000-02-02 ES ES00913350T patent/ES2261190T3/es not_active Expired - Lifetime
- 2000-02-02 DK DK06075430T patent/DK1666026T4/da active
- 2000-02-02 CA CA002361424A patent/CA2361424C/en not_active Expired - Fee Related
- 2000-02-02 EP EP00913350A patent/EP1152749B1/en not_active Expired - Lifetime
- 2000-02-02 PT PT06075430T patent/PT1666026E/pt unknown
- 2000-02-02 KR KR1020087011434A patent/KR20080045300A/ko not_active Application Discontinuation
- 2000-02-02 EP EP06075430.6A patent/EP1666026B2/en not_active Expired - Lifetime
- 2000-02-02 AT AT06075430T patent/ATE537811T1/de active
- 2000-02-02 PT PT00913350T patent/PT1152749E/pt unknown
- 2000-02-02 WO PCT/US2000/002772 patent/WO2000045790A2/en active IP Right Grant
- 2000-02-03 TW TW089101904A patent/TWI292716B/zh active
- 2000-02-03 TW TW096109155A patent/TW200730199A/zh unknown
- 2000-02-07 AR ARP000100524A patent/AR029613A1/es not_active Application Discontinuation
- 2000-02-08 CO CO00007997A patent/CO5140096A1/es unknown
-
2001
- 2001-08-06 ZA ZA200106443A patent/ZA200106443B/xx unknown
- 2001-08-08 NO NO20013861A patent/NO20013861L/no not_active Application Discontinuation
-
2002
- 2002-04-30 HK HK02103234.8A patent/HK1041451B/zh not_active IP Right Cessation
-
2006
- 2006-12-06 HK HK06113414.5A patent/HK1094528A1/xx not_active IP Right Cessation
-
2015
- 2015-05-22 CY CY20121100281T patent/CY1119950T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR029613A1 (es) | Un vehiculo biocompatible estable, no acuoso, de fase unica, formulaciones no acuosas que comprenden el vehiculo y por lo menos un agente benefico suspendido en el mismo y metodos para preparar el vehiculo y las formulaciones. . | |
AR014940A1 (es) | Un portador para la liberacion de un agente bioactivo, un polimero poliester biodegradable, copolimeros y composiciones farmaceuticas que loscontienen. | |
NO175704C (no) | Fremgangsmåte for fremstilling av et stabilt, farmasöytisk preparat av rekombinant interferon | |
KR970706017A (ko) | 안정한 알파 인터페론 수용액 제형(Stable, aqueous alfainterfer on solution for mulations) | |
JP2002536315A5 (es) | ||
CO5580776A2 (es) | Formulacion farmaceutica estable en solucion de oxaliplatino | |
ATE109000T1 (de) | System zur freisetzung von medikamenten und dessen herstellungsmethode. | |
DE69428040D1 (de) | Orale darreichungsform | |
PE20040675A1 (es) | Formulaciones de deposito de liberacion controlada | |
TR200001545T2 (tr) | Plazma proteini içeren farmasötik bileşimler. | |
DK0888110T3 (da) | Mikropartikler af en kompositgel som bærere for aktive midler | |
NZ306156A (en) | Stable protein-phospholipid composition and its use as a carrier | |
AR023044A1 (es) | Composicion farmaceutica soluble en agua en un complejo no ionico y uso del mismo | |
BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
EP2106787A3 (en) | Biodegradable block copolymeric compositions for drug delivery | |
UA83350C2 (ru) | Агрегат с повышенной способностью к деформации, который содержит по крайней мере три амфипатические вещества, для улучшеной транспортировки через полупроницаемые барьеры и для неинвазивного применения лекарственного средства in vivo, в частности через кожу | |
CA2067228A1 (en) | Drug delivery system, method for preparing the same and use thereof | |
CN1989439A (zh) | 治疗葡萄膜炎的方法以及组合物 | |
AR043272A1 (es) | Una microparticula recubierta con una sustancia lipofilica que contiene una droga proteica o antigeno y formulaciones que la comprenden | |
DE69819145D1 (de) | Bioabbaubare mikropartikeln mit verzögerter wirkstofffreisetzung | |
BR9809708A (pt) | Composições farmacêuticas de peptìdeos tendo solubilidade baixa em meio fisiológico | |
ES459244A1 (es) | Un procedimiento para la fabricacion de preparados oftalmi- cos de emision lenta | |
HRP20020071B1 (en) | Pharmaceutical composition and preparation thereof | |
DE60138762D1 (de) | Formulierungen enthaltend dextrin polymere in kombination mit zuckern für die verabreichung von nukleinsäuren | |
KR100906547B1 (ko) | 생활성 물질의 지속적 전달을 위한 겔화 특성을 갖는 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |